Shares of OrthoLogic ( OLGC) were among the worst-performing health-related stocks Wednesday, plunging 49% after the company said its wrist-fracture treatment did not show a statistically significant benefit in a phase III clinical trial. The study's primary endpoint, time to removal of immobilization, was statistically insignificant when compared to a placebo. A secondary endpoint, radiographic evidence of time to radial cortical bridging, did prove statistically significant, however. The company said that it didn't find any differences between its synthetic-peptide Chrysalin treatment and a placebo in other secondary endpoints, though. "We will be conducting a full examination of these results in order to guide our program going forward, including a planned interim analysis of results from the ongoing phase 2b dose-ranging trial of Chrysalin in distal radius fractures, which includes a 30ug dose," the company said. OrthoLogic said it expects to discuss the results of the interim analysis during the third quarter. Shares were trading down $2.55 to $2.64. Somanetics ( SMTS) slid 10% after the medical-device company posted first-quarter results that fell below expectations. The company earned $988,287, or 8 cents a share, on revenue of $5.8 million. Analysts polled by Thomson First Call expected earnings of 9 cents a share on revenue of $6.7 million. During the year-earlier period, the company earned $563,926, or 5 cents a share, on revenue of $4 million. Looking ahead, Somanetics continues to see 2006 earnings of 40 cents to 42 cents a share on revenue growth of about 50%. Analysts project earnings of 41 cents a share on revenue of $30.2 million, or revenue growth of about 47%. Shares were trading down $2.32 to $21.53. Shares of GenVec ( GNVC) rose 4% after the biotechnology company posted a smaller-than-expected fourth-quarter loss. The company reported a loss of $4.1 million, or 6 cents a share, on revenue of $7.8 million. Analysts expected a bigger loss of 9 cents a share on revenue of $5.3 million. During the year-earlier quarter the company posted a loss of $3.7 million, or 7 cents a share, on revenue of $3 million.